Home > Oncology > ESMO 2020 > Gynaecological Cancers > Palbociclib effective in ER-positive endometrial cancer

Palbociclib effective in ER-positive endometrial cancer

ESMO 2020
In the phase 2 PALEO trial, CDK4/6 inhibitor palbociclib in combination with letrozole provided clinically meaningful improvement in progression-free survival (PFS) in patients with ER-positive advanced, recurrent endometrial cancer. Advanced, recurrent endometrial cancer has a dismal prognosis. Carboplatin and paclitaxel are considered to be the first-line systemic treatment of choice. However, no standard treatment has been defined yet for second- or third-line systemic treatment. In the phase 2 PALEO trial, 77 patients with primary stage 4 or relapsed ER-positive endometrial cancer who had 1 or more previous lines of therapy, were enrolled [1]. Prior surgery, radiation therapy, chemotherapy or ≤1 line of endocrine therapy was permitted. Patients were 1:1 randomised to receive letrozole (2.5 mg) plus placebo or letrozole plus palbociclib (125 mg) until progression. Letrozole plus palbociclib significantly improved PFS compared with letrozole plus...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on